Literature DB >> 8114683

O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.

M V Relling1, J Nemec, E G Schuetz, J D Schuetz, F J Gonzalez, K R Korzekwa.   

Abstract

We previously demonstrated that O-demethylation of the pendant dimethoxyphenol ring of epipodophyllotoxins to produce their respective catechol metabolites is catalyzed by cytochrome(s) P450 in human liver microsomes. Our objective was to identify the specific human cytochrome(s) P450 responsible for catechol formation. Using a panel of prototypical substrates and inhibitors for specific cytochromes P450, we identified substrates for CYP3A4 (midazolam, erythromycin, cyclosporin, and dexamethasone) as inhibitors of catechol formation from both etoposide and teniposide. Dexamethasone inhibition was competitive, with Ki values of 60 and 45 microM for etoposide and teniposide, respectively. In 58 human livers, the correlation coefficients for teniposide catechol formation versus 1'- and 4-hydroxymidazolam formation were 80% and 85%, respectively; for etoposide catechol formation versus 1'- and 4-hydroxymidazolam formation r2 was 83% and 79%, respectively. Teniposide and etoposide catechol formation rates were also significantly correlated with immunodetectable CYP3A (r2 = 49% and 51%, respectively) and not with immunodetectable CYP1A2, 2E1, or 2C8. Finally, cDNAs for human CYP3A4, 3A5, 2A6, 2B6, 2C8, and 2C9 were functionally expressed in HepG2 cells, using a vaccinia viral vector. Teniposide and etoposide catechol formation was catalyzed primarily by 3A4 (15.4 and 40.9 pmol/pmol/hr, respectively) and to a lesser degree by 3A5 (1.94 and 11.3 pmol/pmol/hr, respectively), whereas there was no detectable O-demethylation of epipodophyllotoxins by 2A6, 2B6, 2C8, 2C9, or the control virus alone. Moreover, the relative activities of midazolam hydroxylation, compared with O-demethylation of epipodophyllotoxins, were similar for heterologously expressed 3A4 and for human liver microsomes. We conclude that catechol formation from teniposide and etoposide is primarily mediated by human CYP3A4, making these reactions susceptible to inhibition by prototypical 3A substrates and inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114683

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  41 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

3.  Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Authors:  Irina I Vlasova; Wei-Hong Feng; Julie P Goff; Angela Giorgianni; Duc Do; Susanne M Gollin; Dale W Lewis; Valerian E Kagan; Jack C Yalowich
Journal:  Mol Pharmacol       Date:  2010-11-19       Impact factor: 4.436

4.  Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.

Authors:  E S Guns; P L Bullock; M L Reimer; R Dixon; M Bally; L D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

5.  Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.

Authors:  C Brimer; J T Dalton; Z Zhu; J Schuetz; K Yasuda; E Vanin; M V Relling; Y Lu; E G Schuetz
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

6.  Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.

Authors:  Marzia Del Re; Tiziana Latiano; Leonardo Fidilio; Giuliana Restante; Franco Morelli; Evaristo Maiello; Romano Danesi
Journal:  EPMA J       Date:  2017-03-07       Impact factor: 6.543

7.  Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

Authors:  Huw D Thomas; David J Porter; Imke Bartelink; Joy R Nobbs; Michael Cole; Suzie Elliott; David R Newell; A Hilary Calvert; Martin Highley; Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

8.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

Authors:  Jun J Yang; Cheng Cheng; Wenjian Yang; Deqing Pei; Xueyuan Cao; Yiping Fan; Stanley B Pounds; Geoffrey Neale; Lisa R Treviño; Deborah French; Dario Campana; James R Downing; William E Evans; Ching-Hon Pui; Meenakshi Devidas; W P Bowman; Bruce M Camitta; Cheryl L Willman; Stella M Davies; Michael J Borowitz; William L Carroll; Stephen P Hunger; Mary V Relling
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

9.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

10.  Human liver microsomal metabolism of paclitaxel and drug interactions.

Authors:  P B Desai; J Z Duan; Y W Zhu; S Kouzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.